<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Widely discussed potential agents for the treatment of SARS-CoV-2 infection.</p>
 </caption>
 <alt-text id="alttext0020">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Agent</th>
    <th>Chemical
     <break/>Formula
    </th>
    <th>Chemical
     <break/>Structure
    </th>
    <th>Comments</th>
    <th>Clinical status</th>
    <th>References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Chloroquine (Antimalarial)</td>
    <td align="left">C
     <sub>18</sub>H
     <sub>26</sub>ClN
     <sub>3</sub>
    </td>
    <td align="left">
     <inline-graphic xlink:href="fx2_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0025">Image 2</alt-text>
     </inline-graphic>
    </td>
    <td align="left">Chloroquine has shown 
     <italic>in vitro</italic> efficacy against SARS-CoV-2 with an EC50 (half-maximum effective concentration) value of 5.47 μM at 48 h. Data from over 100 COVID-19 patients have demonstrated that chloroquine phosphate is superior to control treatment.
    </td>
    <td align="left">NCT04307693, NCT04320277, NCT04323527, NCT04306497, NCT04325893, NCT04323592, NCT04315948
     <break/>ChiCTR2000030031, ChiCTR2000029741, ChiCTR2000029740, ChiCTR2000029868, ChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029988, ChiCTR2000029542.
    </td>
    <td align="left">(
     <xref rid="bib44" ref-type="bibr">Gao et al., 2020</xref>; 
     <xref rid="bib157" ref-type="bibr">Yao et al., 2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Hydroxychloroquine (Antimalarial)</td>
    <td align="left">C
     <sub>18</sub>H
     <sub>26</sub>ClN
     <sub>3</sub>O
    </td>
    <td align="left">
     <inline-graphic xlink:href="fx3_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0030">Image 3</alt-text>
     </inline-graphic>
    </td>
    <td align="left">Hydroxychloroquine was found to have a strong anti-SARS-CoV-2 effect (
     <italic>in vitro</italic>) with an EC50 value of 0.72 μM at 48 h. Clinical findings involving 36 COVID-19 patients have shown considerable viral load suppression in patients treated with hydroxychloroquine as compared to control patients.
    </td>
    <td align="left">NCT04308668, NCT04325893, NCT04328467, NCT04329923, NCT04321278, NCT04307693, NCT04320277, NCT04315948, NCT04326725,
     <break/>ChiCTR2000029740, ChiCTR2000029868, ChiCTR2000029899, ChiCTR2000029898.
    </td>
    <td align="left">(
     <xref rid="bib45" ref-type="bibr">Gautret et al., 2020</xref>; 
     <xref rid="bib157" ref-type="bibr">Yao et al., 2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Lopinavir/Ritonavir (HIV-1 protease Inhibitor)</td>
    <td align="left">C
     <sub>37</sub>H
     <sub>48</sub>N
     <sub>4</sub>O
     <sub>5</sub>
     <bold>/</bold> C
     <sub>37</sub>H
     <sub>48</sub>N
     <sub>6</sub>O
     <sub>5</sub>S
     <sub>2</sub>
    </td>
    <td align="left">
     <inline-graphic xlink:href="fx4_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0035">Image 4</alt-text>
     </inline-graphic>
    </td>
    <td align="left">de Wilde et al. recognized the lopinavir's antiviral activity against SARS-CoV and showed an EC50, 17.1 ± 1 μM in Vero E6 cells. In a study involving 199 COVID-19 patients (99 assigned to a lopinavir/ritonavir group and 100 patients to the standard treatment. Group) reported that no benefit with lopinavir/ritonavir treatment beyond standard care was observed in hospitalized adult patients with severe COVID-19.</td>
    <td align="left">NCT04255017, NCT04315948, NCT04330690, NCT04252885, NCT04261907, NCT04276688, NCT04307693,
     <break/>ChiCTR2000029539, ChiCTR2000029387, ChiCTR2000030218, ChiCTR2000029741.
    </td>
    <td align="left">(
     <xref rid="bib12" ref-type="bibr">Cao et al., 2020</xref>; 
     <xref rid="bib30" ref-type="bibr">de Wilde et al., 2014</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Remdesivir (Antiviral)</td>
    <td align="left">C
     <sub>27</sub>H
     <sub>35</sub>N
     <sub>6</sub>O
     <sub>8</sub>P
    </td>
    <td align="left">
     <inline-graphic xlink:href="fx5_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0040">Image 5</alt-text>
     </inline-graphic>
    </td>
    <td align="left">Wang et al. demonstrated that remdesivir inhibits SARS-CoV-2 infection in Vero E6 cells (EC50 = 0.77 μM). Holshue et al. reported that remdesivir treatment leads to remarkable results in the care of a first COVID-19 patient in the United States.</td>
    <td align="left">NCT04252664, NCT04257656, NCT04280705, NCT04292730, NCT04292899, NCT04315948, NCT04335123,</td>
    <td align="left">(
     <xref rid="bib57" ref-type="bibr">Holshue et al., 2020</xref>; 
     <xref rid="bib146" ref-type="bibr">Wang et al., 2020</xref>, 
     <xref rid="bib147" ref-type="bibr">Wang et al., 2020b</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Favipiravir (Antiviral)</td>
    <td align="left">C
     <sub>5</sub>H
     <sub>4</sub>FN
     <sub>3</sub>O
     <sub>2</sub>
    </td>
    <td align="left">
     <inline-graphic xlink:href="fx6_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0045">Image 6</alt-text>
     </inline-graphic>
    </td>
    <td align="left">Preliminary findings from a total of 80 patients suggested that the antiviral activity of favipiravir was more efficient than that of lopinavir/ritonavir. In a study involving 240 COVID-19 patients, favipiravir was considered as preferred treatment as compared to arbidol.</td>
    <td align="left">NCT04336904, NCT04310228,
     <break/>ChiCTR2000030113.
    </td>
    <td align="left">
     <xref rid="bib16" ref-type="bibr">Chen et al., 2020a</xref>, 
     <xref rid="bib17" ref-type="bibr">Chen et al., 2020b</xref>, 
     <xref rid="bib18" ref-type="bibr">Chen et al., 2020c</xref>, 
     <xref rid="bib19" ref-type="bibr">Chen et al., 2020d</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Arbidol (Umifenovir) (Antiviral)</td>
    <td align="left">C
     <sub>22</sub>H
     <sub>25</sub>BrN
     <sub>2</sub>O
     <sub>3</sub>S
    </td>
    <td align="left">
     <inline-graphic xlink:href="fx7_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0050">Image 7</alt-text>
     </inline-graphic>
    </td>
    <td align="left">According to a report, arbidol at a concentration range of 10–30 μM 
     <italic>in vitro</italic> is effective against SARS-COV-2.
     <break/>In a clinical study involving 111 COVID-19 patients-infected pneumonia, it was found that arbidol could accelerate and enhance the process of viral clearance whereas, in another study, arbidol in combination with Lopinavir/ritonavir showed beneficial effects.
    </td>
    <td align="left">NCT04252885, NCT04254874, NCT04255017, NCT04260594,
     <break/>ChiCTR2000029573.
    </td>
    <td align="left">(
     <xref rid="bib16" ref-type="bibr">Chen et al., 2020a</xref>, 
     <xref rid="bib17" ref-type="bibr">Chen et al., 2020b</xref>, 
     <xref rid="bib18" ref-type="bibr">Chen et al., 2020c</xref>, 
     <xref rid="bib19" ref-type="bibr">Chen et al., 2020d</xref>; 
     <xref rid="bib32" ref-type="bibr">Deng et al., 2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Azithromycin (Antibiotic)</td>
    <td align="left">C
     <sub>38</sub>H
     <sub>72</sub>N
     <sub>2</sub>O
     <sub>12</sub>
    </td>
    <td align="left">
     <inline-graphic xlink:href="fx8_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0055">Image 8</alt-text>
     </inline-graphic>
    </td>
    <td align="left">In a clinical study involving 36 COVID-19 patients (on the sixth day from the start of treatment), all the patients treated with hydroxychloroquine and azithromycin combination were virologically cured as compared to 57.1% patients treated with hydroxychloroquine alone.</td>
    <td align="left">NCT02735707, NCT04321278,</td>
    <td align="left">
     <xref rid="bib45" ref-type="bibr">Gautret et al. (2020)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Baricitinib (Anti-inflammatory)</td>
    <td align="left">C
     <sub>16</sub>H
     <sub>17</sub>N
     <sub>7</sub>O
     <sub>2</sub>S
    </td>
    <td align="left">
     <inline-graphic xlink:href="fx9_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0060">Image 9</alt-text>
     </inline-graphic>
    </td>
    <td align="left">Baricitinib can be a potential treatment for SARS-CoV-2 to inhibit viral entry and inflammation due to its affinity for AP2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK).</td>
    <td align="left">NCT04320277.</td>
    <td align="left">(
     <xref rid="bib119" ref-type="bibr">Richardson et al., 2020</xref>; 
     <xref rid="bib131" ref-type="bibr">Stebbing et al., 2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Tocilizumab (Immunosuppressive)</td>
    <td align="left">C
     <sub>6428</sub>H
     <sub>9976</sub>N
     <sub>1720</sub>O
     <sub>2018</sub>S
     <sub>42</sub>
    </td>
    <td/>
    <td align="left">Tocilizumab is a recombinant monoclonal antibody against the human interleukin 6 (IL-6) receptor.
     <break/>A study involving 21 patients treated with tocilizumab in China demonstrated rapid improvement, and about 90.5% (19) were discharged on average of 13.5 days after the treatment.
    </td>
    <td align="left">NCT04306705, NCT04310228, NCT04317092, NCT04324047,
     <break/>ChiCTR2000029765.
    </td>
    <td align="left">
     <xref rid="bib153" ref-type="bibr">Xu et al. (2020)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Convalescent plasma</td>
    <td/>
    <td/>
    <td align="left">A case study, five critically ill COVID-19 and ARDS (acute respiratory distress syndrome) patients received convalescent plasma from 5 COVID-19 recovered patients showed remarkable improvement in the clinical status of patients within 12days after the transfusion.</td>
    <td align="left">NCT04292340,
     <break/>ChiCTR2000029850, ChiCTR2000030039, ChiCTR2000030046, ChiCTR2000030627.
    </td>
    <td align="left">
     <xref rid="bib128" ref-type="bibr">Shen et al. (2020)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Stem cell therapy</td>
    <td/>
    <td/>
    <td align="left">In a case study, seven COVID-19 patients were administered with human Mesenchymal stem cells (MSCs) (10
     <sup>6</sup> cells per kilogram of weight) intravenously. The symptoms in all the patients and pulmonary functions improved in 2 days significantly after transplantation, and also no adverse effects were observed for 14 days.
    </td>
    <td align="left">NCT04252118, NCT04269525, NCT04288102, NCT04313322, NCT04331613,
     <break/>ChiCTR2000029580.
    </td>
    <td align="left">
     <xref rid="bib76" ref-type="bibr">Leng et al. (2020)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Interferons</bold>
    </td>
    <td/>
    <td/>
    <td align="left">In an 
     <italic>in vitro</italic> study, pre-treatment of recombinant type I IFN-α showed a significant reduction in SARS-CoV-2 viral replication. IFN- α has also been recommended for the treatment of COVID-19 in Chinese guidelines.
    </td>
    <td align="left">NCT04276688, NCT04315948, NCT04320238,
     <break/>ChiCTR2000029387, ChiCTR2000029638, ChiCTR2000030480, ChiCTR2000030082, ChiCTR2000030535.
    </td>
    <td align="left">(
     <xref rid="bib26" ref-type="bibr">Commision, 2020</xref>; 
     <xref rid="bib83" ref-type="bibr">Lokugamage et al., 2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">
     <bold>Corticosteroids</bold>
    </td>
    <td/>
    <td/>
    <td align="left">Due to the high amount of cytokines in COVID-19 patients, corticosteroids are frequently used to treat patients with severe illness. For COVID-19 patients with severe illness, glucocorticoids can be used for a short period (3–5 days), and a higher dose should be avoided as it will delay the coronavirus clearance due to immunosuppressive effects.
     <break/>However, preliminary results of the RECOVERY Trial involving dexamethasone (6 mg given once daily for ten days) showed reduced mortality in patients receiving respiratory support.
    </td>
    <td align="left">NCT04273321,
     <break/>NCT04244591,
     <break/>NCT04323592,
     <break/>NCT04381936,
     <break/>NCT04325061,
     <break/>NCT04347980,
     <break/>NCT04395105,
     <break/>NCT04344730,
     <break/>NCT04327401,
     <break/>NCT04445506,
     <break/>NCT04402840.
    </td>
    <td align="left">(
     <xref rid="bib26" ref-type="bibr">Commision, 2020</xref>; 
     <xref rid="bib59" ref-type="bibr">Huang et al., 2020</xref>; 
     <xref rid="bib58" ref-type="bibr">Horby et al., 2020</xref>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
